Goldman Sachs Group Inc. Purchases New Holdings in Selecta Biosciences Inc. (SELB)

Goldman Sachs Group Inc. bought a new stake in Selecta Biosciences Inc. (NASDAQ:SELB) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 29,462 shares of the company’s stock, valued at approximately $289,000. Goldman Sachs Group Inc. owned about 0.13% of Selecta Biosciences as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the stock. Bank of New York Mellon Corp increased its holdings in Selecta Biosciences by 26.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 41,020 shares of the company’s stock valued at $748,000 after purchasing an additional 8,620 shares during the last quarter. Schwab Charles Investment Management Inc. increased its holdings in Selecta Biosciences by 50.3% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 29,600 shares of the company’s stock valued at $541,000 after purchasing an additional 9,900 shares during the last quarter. Geode Capital Management LLC increased its holdings in Selecta Biosciences by 12.1% in the 4th quarter. Geode Capital Management LLC now owns 92,803 shares of the company’s stock valued at $910,000 after purchasing an additional 9,988 shares during the last quarter. Wells Fargo & Company MN increased its holdings in Selecta Biosciences by 125.8% in the 4th quarter. Wells Fargo & Company MN now owns 23,491 shares of the company’s stock valued at $230,000 after purchasing an additional 13,086 shares during the last quarter. Finally, Keybank National Association OH acquired a new stake in Selecta Biosciences in the 4th quarter valued at approximately $143,000. Hedge funds and other institutional investors own 50.14% of the company’s stock.

Several equities analysts have commented on the stock. Zacks Investment Research cut shares of Selecta Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, January 10th. BidaskClub raised shares of Selecta Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Thursday, March 15th. Mizuho assumed coverage on shares of Selecta Biosciences in a research report on Monday, February 26th. They issued a “buy” rating and a $30.00 price target for the company. ValuEngine cut shares of Selecta Biosciences from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Finally, Canaccord Genuity reissued a “buy” rating and issued a $30.00 price target on shares of Selecta Biosciences in a research report on Thursday, January 18th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $23.33.

Shares of SELB stock opened at $11.72 on Tuesday. The company has a debt-to-equity ratio of 0.41, a current ratio of 9.00 and a quick ratio of 9.00. Selecta Biosciences Inc. has a 52 week low of $7.95 and a 52 week high of $24.02. The company has a market capitalization of $267.75, a price-to-earnings ratio of -3.66 and a beta of -3.53.

Selecta Biosciences (NASDAQ:SELB) last issued its quarterly earnings results on Thursday, March 15th. The company reported ($0.88) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.56) by ($0.32). Selecta Biosciences had a negative net margin of 31,556.04% and a negative return on equity of 110.64%. The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $15.00 million. equities analysts forecast that Selecta Biosciences Inc. will post -3.28 EPS for the current fiscal year.

Selecta Biosciences Profile

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.

Institutional Ownership by Quarter for Selecta Biosciences (NASDAQ:SELB)

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply